Get started
Author

Coline Le Meur

Observed names: Coline LE MEUR, Coline LE Meur
ORCID: 0009-0007-5861-7264
Observed ORCID: 0009-0007-5861-7264
OpenAlex ID: A5009964307
HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker
2024 · Karim Amrane, Coline Le Meur, et al. · Frontiers in Immunology · 26
PDF
Case report: Eosinophilic fasciitis induced by pembrolizumab with high FDG uptake on 18F-FDG-PET/CT
2022 · Karim Amrane, Coline Le Meur, et al. · Frontiers in Medicine · 15
PDF
Review on radiomic analysis in 18F-fluorodeoxyglucose positron emission tomography for prediction of melanoma outcomes
2024 · Karim Amrane, Coline Le Meur, et al. · Cancer Imaging · 10
PDF
Prognostic value of pre-therapeutic FDG-PET radiomic analysis in gastro-esophageal junction cancer
2023 · Karim Amrane, Philippe Thuillier, et al. · Scientific Reports · 10
PDF
MHC class II: a predictor of outcome in melanoma treated with immune checkpoint inhibitors
2025 · Karim Amrane, Pierre Le Noac’h, et al. · Melanoma Research · 3
Case report: Thoracic schwannoma as a diagnostic pitfall in both 18F-Choline PET/CT and 18F-FDG PET/CT
2024 · Karim Amrane, Coline Le Meur, et al. · Frontiers in Oncology · 3
PDF
Case Report: Complete metabolic responses to trastuzumab–deruxtecan in HER2-altered solid tumors: two illustrative cases
2026 · Coline Le Meur, Pierre-Yves Le Roux, et al. · Frontiers in Immunology · 2
PDF
Case Report: Long-term metabolic response of metastatic uveal melanoma to pembrolizumab on FDG-PET/CT despite a serial pseudoprogressions phenomenon
2023 · Karim Amrane, Coline Le Meur, et al. · Frontiers in Immunology · 2
PDF
18F-FDG PET radiomic analysis to predict outcomes in metastatic melanoma treated with immune checkpoint inhibitors
2026 · Karim Amrane, Coline Le Meur, et al. · Frontiers in Immunology · 1
PDF
Author Correction: Prognostic value of pre-therapeutic FDG-PET radiomic analysis in gastro-esophageal junction cancer
2023 · Karim Amrane, Philippe Thuillier, et al. · Scientific Reports · 1
PDF
Pretreatment spatial immune architecture and 1-year clinical benefit to first-line ICB in advanced melanoma.
2026 · Karim Amrane, Patrice Hemon, et al. · Journal of Clinical Oncology
Prognostic value of TMTV and Dmax calculated from 18F-fluorodeoxyglucose positron emission tomography images in metastatic cutaneous melanoma treated with immune checkpoint blockade
2026 · Karim Amrane, Bastien Cabarrou, et al. · European Journal of Nuclear Medicine and Molecular Imaging
Overcoming anti-PD-L1 resistance with anti-PD1 therapy: A case report and putative rationale
2026 · Karim AMRANE, Coline LE MEUR, et al. · European Journal of Cancer
Survival impact of a KEAP1-NFE2L2 radiomics model in PDL1 ≥ 50% non-small cell lung cancer treated with pembrolizumab: the PEMBROMIC study
2025 · Coline Le Meur, Karim Amrane, et al. · Cancer Imaging
PDF
Pituitary Metastasis of Non–Small Cell Lung Cancer With High FDG Uptake on PET/CT Pituitary Metastasis of Non–Small Cell Lung Carcinoma
2022 · Coline Le Meur, Luca Campedel, et al. · Clinical Nuclear Medicine
Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer
2021 · Karim Amrane, Luca Campedel, et al. · Frontiers in Medicine
PDF
Works count: 16
Citation count: 73
H-index: 4
I10-index: 4
Year
Topic
Type